Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Clinical Chemistry > TDM > Flashcards

TDM Flashcards

You may prefer our related Brainscape-certified flashcards:
Periodic Table flashcards Chemistry 101 flashcards AP® Chemistry flashcards Organic Chemistry 101 flashcards
1
Q

What is therapeutic drug monitoring?

A

The measurement of blood drug concentrations for the purpose of ensuring adequate and effective treatment while avoiding potential toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the therapeutic and toxic response to a drug directly related to?

A

The therapeutic (and toxic) response to a drug is directly related to its concentration at some specific “receptor”
AND
The blood concentration of the drug reflects the concentration at the target receptor.

We can’t sample the receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the concept of the therapeutic range?

A

A range of serum drug concentrations associated with effective therapy but w/o significant toxicity or side effects

Analogous to reference interval

Derived from clinical studies (drug trials)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why do TDM?

A

Optimize dose and therapeutic response
—Undertreatment may be dangerous

Avoid toxicity
—-Overtreatment may be dangerous

Detect changes or variability in pharmacokinetics

Monitor compliance
—Is the patient taking the drug as prescribed?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is pharmacokinetics?

A

What the body does to a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ADME stands for?

A

Absorption
Distribution
Metabolism
Elimination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is pharmacodynamics?

A

What the drug does to the body

effects and mechanism of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

A single drug dose does ____result in the same ________dose in everyone.

A

NOT,

DOSE CONCENTRATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pharmacological response is caused by ?

A

free drug bound to receptor site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are three ways to administer drugs? Describe the absorption and variability for each.

A

Intravenous administration

  • –“instantaneous” and complete – not a variable
  • –requires professional administration = cost

Intramuscular or subcutaneous
—-slower

Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is meant by distribution of a drug? What can it be affected by?

A

Delivery of a drug to various compartments
central – blood (and interstitial fluid) = ECF
peripheral – other tissues/organs

Distribution is affected by:

  • —binding to blood proteins
  • —lipophilicity (high distribution by depositing in fat)
  • —specific binding in tissues (ie: digoxin bound up in heart and muscle/specific receptors bind tightly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why do we not draw drug levels during distribution phase?

A

Because blood levels overestimate how much drug is actually taken up by tissues.
Drug levels should be drawn AFTER distribution is complete.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are two proteins that bind drugs?

A

Albumin

  • –binds acid & neutral drugs
  • ——–phenytoin, carbamazepine, VPA

α1-acid glycoprotein (AAG, orosomucoid)
—binds basic drugs
——lidocaine, tricyclic antidepressants
acute phase reactant (increases during acute reaction)
—Drugs bound ≥90% may be appropriate for free drug measurement (don’t do often)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How are drugs eliminated?

A

Hepatic Metabolism
—hepatic disease may alter dosing for drugs —–cleared primarily by metabolism

Renal Elimination
—decreased creatinine clearance (eGFR) may alter dosing for drugs cleared by excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

During drug metabolism how does the body’s reaction affect metabolism?

A

Reactions are designed to “de-toxify” the drug and/or increase its polarity for urinary excretion

Reactions may also form active drug (prodrug) or a toxin

Hepatic cytochrome P450 (CYP) system
18 CYP families, 43 sub-families, involved in:
drugs & other (3 families: CYP1, CYP2, CYP3)
genetic variability – pharmacogenetics (-omics)
warfarin –
VKORC1 – warfarin target
CYP2C9 – warfarin metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Michaelis-Menton kinetiics relationship to drug metabolism?

A

Michaelis-Menten kinetics (1st order to drug)

  • –metabolizing enzymes are in excess of drug concentration
  • –doubling dose approximately doubles drug concentration
  • –True for most drugs at typical therapeutic concentrations
Saturation kinetics (zero order to drug)
---therapeutic concentrations overload metabolic enzymes
----inc. dose has a disproportionate increase in drug level
-----phenytoin (therapeutic range  ~ sat’n)
ethanol (sat’n at >0.02%) – legally drunk  = 0.08%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In first order kinetics (exponential) elimination rate depends on ? (most drugs eliminated by first order kin)

A

drug concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is a drug half-life?

A

Half-life (T½): the time for the blood drug concentration to decrease by 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the peak?

A

Peak – time at which the concentration (at the site of action) is highest

  • –draw after distribution phase complete
  • –not commonly used (Antibiotics only?)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is trough? JBND?

A

Trough – time of the lowest concentration

JBND – just before next dose
appropriate draw time for most drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is steady state in repetitive dosing?

DEFINITE TEST QUESTION

A

Steady-state – net equilibrium between drug intake and elimination

Time to reach steady-state is solely a function of half-life

Don’t draw levels before 4-5 half-lives from initiation or after change in dosing

22
Q

When do we use TDM?

A
  • Drugs with narrow (low) therapeutic index
  • Treatment failure – distinguish compliance vs. unusual pharmacokinetics
  • Assess adequacy when clinical indicators evasive
  • –prevent seizures, don’t titrate
  • —prevent rejection, don’t hope to salvage
  • Toxicity mimics disease (digoxin, PA, phenytoin)
  • Toxicity cannot be tolerated
  • Likely PK aberrations (drug interactions, polymorphisms, hepatic or renal disease, pregnancy)
23
Q

What is the therapeutic index?

A

Therapeutic Index = Toxic conc. ÷ Therapeutic conc.

24
Q

TDM measuring methods

A

Immunoassay – preferred method for most

  • homogeneous (EMIT, CEDIA, KIMS)
  • –adaptable to most standard chemistry analyzers
  • fluorescence polarization – Roche Integra
  • heterogeneous – often chemiluminescent
  • –standard immunassay analyzers

HPLC – flexible but poorly automated
—Useful if no commercial assay available
(manual work ie precipitation before)
-mult drugs can be measures unlike immunoassay

GLC – ditto, but often requires derivatization, sometimes drugs dont exist in gas form

25
Q

When should TDM be sampled?

A
  • Steady-state required (4-5 half-lives)
  • JBND (just before next dose, “trough”) – suitable for most drugs.
  • Peak – occasionally for antibiotics
  • —well-defined for i.v. drugs
  • –more variable for oral, i.m. or subcutaneous
  • –relation to distribution phase
  • Ideally, dosing info is available – but reality?
  • —dose, time of dose, route (CAP checklist)
26
Q

What are TDMs drawn in?

A

Gel barrier tubes:
SST (B-D) – dec. in phenytoin, lidocaine, carbamazepine
Corvac (Tyco Kendall) – dec. in lidocaine only
Greiner – no effects? (no peer-reviewed study?)

Gel adsorbs or dissolves drug. Decrease is dependent upon drug, sample volume and duration of contact

Reference labs usually have blanket no SST rule for all drugs, whether affected or not

27
Q

What is the only Cardioactive drug that is monitored today really?

A

Digoxin

Uncommonly monitored:
Procainamide
Lidocaine
Quinidine

Rarely monitored
flecainide, tocainide, amiodarone, verapamil, disopyramide, diltiazem, nifedipine

28
Q

Digoxin

A

Natural product – foxglove plant

Therapeutic 0.8-2.0 ng/mL, toxicity may be seen at 1.5 ng/mL

= LOW THERAPEUTIC INDEX
children may tolerate up to 4.0 ng/mL

Renal excretion req. dosage adjustment in renal disease

Half-life 30-45 hrs

Long distribution: draw ≥8 hrs post dose (JBND preferred)

Increased toxicity with ↓K+, ↓Mg2+, ↑Ca2+

Quinidine → ↑digoxin levels

Measure by immunoassay

29
Q

Digoxin assay interferences?

A

DLIS – digoxin-like immunoreactive substance
steroids – synthesized in the adrenal (“cardenolides”)
increased in pregnant women and newborns
increased in renal, hepatic and cardiac failure
assay dependent interference – check drug-free patients

Aldactone (spironolactone) - K+ sparing diuretic
neg. interference – IMx, AxSym, Dimension
pos. interference – TDx, Elecsys
no interference – EMIT, Vitros, Tina-Quant (Roche latex)

Fab fragment of digoxin antibody
Given to treat digoxin overdose
May interfere (positive) with digoxin assays:
marked – Immulite, Vitros, Dimension, Access
moderate – Elecsys, Integra, EMIT, Centaur
minimal – AxSym, Synchron, CEDIA
Ultrafiltration allows “accurate” free digoxin level

30
Q

Procainamide

A

Hepatic metabolism – N-acetylation to NAPA
PA and NAPA both active, always measure both
Fast acetylators (half-life ~3 hrs)
PA:NAPA ≥ 1.0 @ 3 hr post dose
Slow acetylators (half-life ~5 hours)
PA:NAPA > 2.0 @ 3 hrs post dose
more likely to develop lupus-like syndrome
Japan - 10%, Mediterranean - 90%, U.S. Caucasian - 50%
Measure by immunoassay, HPLC

31
Q

Anticonvulsants

A 
Carbamazepine (CBZ, Tegretol®), Oxcarbazepine (Trileptal®)
Phenobarbital (ΦB); Primidone (Mysoline®)
Phenytoin (DPH, Dilantin®), Fosphenytoin (Cerebryx®)
Valproic Acid (VPA, Depakene®)
Primidone (Mysoline®)
Ethosuximide (Zarontin®)
Clonazepam (Klonopin®)
Gabapentin (Neurontin®)
Lamotrigine (Lamictal®)
Felbamate (Felbatol®)
Zonisamide (Zonergan®)
Levitiracetam (Keppra ®)
Tiagabine – (Gabitril®)
32
Q

Carbamazepine (CBZ)

A 
Tegretol®
80% protein bound (± free drug monitoring)
Hepatic metabolism – induced by DPH, ΦB, and CBZ
CBZ-10,11-epoxide active metabolite
may accumulate in children w/ nl CBZ
Erratic absorption
T1/2 15-20 hrs
Therapeutic range 4-12 mcg/mL
Monitor trough levels
33
Q

Phenytoin

A

Dilantin® - diphenylhydantoin (DPH)
~90% protein bound
candidate for free drug monitoring (esp. in renal patients)-things displacing pheny from albumin increasing free and decreasing bound
Low H2O solubility: erratic oral & im absorp.

Hepatic metabolism – T1/2 ≈ 20 hrs
metabolism begins to saturate >5 mcg/mL
induced by EtOH, PB and CBZ
comp. by cimetidine, dicumarol, INH

Protein binding competition by ASA and VPA
Collect samples JBND (no SST tubes)
Therapeutic range 10-20 mcg/mL, critical >35-40
Free phenytoin – therapeutic range 1.0-2.0 mcg/mL
90% bound, 10% free

34
Q

Phebobarbital

A

40-60% protein bound
Hepatic metabolism – T1/2 70-100 hrs
draw trough levels
Induces metabolism of other drugs (DPH, CBZ)
Dec. clearance with VPA and ASA (↑10-20%)
Ther. range 15-40 mcg/mL, critical >80 mcg/mL

35
Q

Primidone

A

Mysoline®
Metabolized to phenobarbital (PB) (T1/2 = 10 h)
monitor both, steady state depends on phenobarbital
Therapeutic range 5-12 mcg/mL, toxic >15 mcg/mL
DPH → ↑ PB:Prm due to dec. PB metab.
VPA decreases clearance of PB and Prm
Collect JBND

36
Q

Valproic Acid

A

Depakene®
Hepatic metabolism (T1/2 16→12 hrs, 8 in children)
short T1/2 in children can lead to subtherapeutic levels
>90% protein bound, dec. in uremia, cirrhosis
competes w/ DPH (slide 15)
Hepatotoxic – monitor LFT’s (esp. ALT)
Not recommended during pregnancy (teratogenic)
Draw JBND

37
Q

Theophylline

A

Aminophylline, TheoDur (sustained release)
bronchodilator – asthma, neonatal apnea
largely replaced by ß2-agonists
Hepatic metabolism (half-life 3-11 hrs)
saturation occurs ≈ 20 mcg/mL
Therapeutic range 10-20 mcg/mL, toxic >25-30
Neonatal apnea – 5-10 mcg/mL (caffeine preferred)
Peak – 2 hrs w/o food, 3-5 w/ food or SR
Measure peak or trough (rare now)

38
Q

Caffeine

A 
Treat neonatal apnea
Advantages over theophylline:
less frequent dosing
more central respiratory stimulation
less peripheral cardiovascular toxicity
Therapeutic range – 8-20 mcg/mL
Measure by HPLC or immunoassay
39
Q

Which antibiotics can we use TDM on?

A 
Aminoglycosides
Gentamicin, Tobramycin, Amikacin
Vancomycin
Anti-tubercular
INH, Rifampin, Ethambutol, Pyrazinamide
Rare
40
Q

Aminoglycosides

A

Gentamicin, Tobramycin, Amikacin
Bactericidal against aerobic gram-negatives
O2 dependent active transport into bacteria
often combined w/ cell wall Abx (e.g., penicillins)
Poor oral absorption, given iv or im
Vd ≈ 0.2 L/kg, consistent with blood & ECF
Vd – volume of distribution
100% renal excretion, T1/2 2-3 hrs
Renal disease req. dec. dose and/or inc. dosing interval

***nephrotoxic

41
Q

Historical protocol for Aminoglycosides

A

Historical protocols:
dosed tid (3/day, iv or im), draw peak & trough
peak – 4-10 mcg/mL (20-30 amikacin)
15-30 min. post iv infusion
2 hrs post im-injection
trough - therapeutic (?)
nephrotoxicity (reversible) at trough > therapeutic

42
Q

Modern protocol for Aminoglycosides

A 
Current protocols:
Once-a-day dosing
same total dose (3-5 mg/kg IBW/day)
no levels if 60 mL/min
goal is 18 hr post level
43
Q

Aminoglycosides sampling

A

Heparin – binds aminoglycosides, blocks antigenicity (hep neg and amino positive so attracts and then antibodies cant see aminogly so false low levels)
No green top tubes
Carbenicillin, ticarcillin, piperacillin
covalent binding – blocks antigenicity and action
assay quickly or freeze after separation
Measured by immunoassay

44
Q

Vancomycin

A

Glycopeptide – unrelated to aminoglycosides
Effective against gram-pos bacteria
Enterococci developing resistance (VRE)
Given iv
Monitor by immunoassay:
peak (30 min post iv) – 30-50 mcg/mL
trough (JBND) – 5-15 (to 20 in hosp. acquired pneumonia, osteomyelitis)
ototoxicity and nephrotoxicity low (historical?)
CDP-1 – degradation product that cross-reacts in some assays, esp. in renal patients
Poor standardization among manufacturers
Up to 35% variance

45
Q

Immunosuppressants

A

Cyclosporine A
Tacrolimus (ProGraf, FK-506)
Sirolimus (Rapamycin)
Mycophenolic acid

All are isolated from molds
Block T-lymphocyte proliferation via several mechanisms
Prevent T-cell mediated organ rejection

46
Q

Cyclosporin A

A

Targets levels vary with organ and duration of therapy
Whole blood is preferred sample
Draw trough levels after 3-5 days therapy
Measure by immunoassay (req. pretreatment) or LC-MS/MS
Many metabolites, therefore immunoassay results may be higher than LC-MS/MS, esp. with polyclonal assays

47
Q

Tacrolimus

A 
Less nephrotoxic than cyclosporine
Slight neurotoxicity in ≤5% of patients
Therapeutic range 3-15 ng/mL
Collect whole blood after at least 5 days
Measure by immunoassay or LC-MS/MS
48
Q

Sirolimus

A

Structural, mechanistic similarity to FK-506
Collect whole blood JBND after 3 days
Measure by LC-MS/MS or immunoassay
Keep trough levels >30 ng/mL for 8 wks, then maintain >15 ng/mL
Values above 60 ng/mL associated with significant complications

49
Q

Mycophenolic Acid (MPA)

A 
MMF - prodrug hydrolyzed in liver to MPA
Conjugation to MPA-glucuronide (MPAG)
Monitor trough levels in serum/plasma:
MPA – 1.0-3.5 mcg/mL
MPAG – 35-100 mcg/mL (value?)
Immunoassay or LC-MS/MS
50
Q

Psychoactive drugs

A

Lithium
(Tri)cyclic antidepressants
SSRI’s – selective serotonin reuptake inhibitors
Antipsychotic (neuroleptics)

*Except for lithium, rarely need monitoring

51
Q

Lithium

A

Used to treat manic phase of bipolar disorder
Administered as Li2CO3. Draw JBND
Very low therapeutic index
therapeutic range: 0.5 -1.2 mM
mild toxicity: >1.5 mM (not life-threatening)
severe toxicity: >2.5 mM (seizures)
Renal excretion, dehydration increases toxicity
Therapeutic effects are delayed

52
Q

Lithium Measurment

A 
Flame photometry – outdated
Atomic absorption (flame) - cumbersome
Ion-selective electrode – semi-automated
Electrode has slight Na interference
Measure (and QC) both Na & Li and correct mathematically
Chemical – adaptable to chemistry analyzers
Substituted proprietary porphyrin
Li-dependent phosphatase

Clinical Chemistry (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions